Medscape

Proton Pump Inhibitors May Increase Fracture Risk, FDA Warns

May 25, 2010 — The US Food and Drug Administration (FDA) today recommended that physicians exercise more caution in prescribing proton pump inhibitors (PPIs) in light of evidence suggesting that high ...
FOX8 Cleveland

Renexxion Ireland has Completed a Successful Pre-IND Consultation with the United States FDA for Development of Naronapride for Patients with PPI-non-responsive Symptomatic GERD

ROSCREA, Ireland, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet ...
Medscape

Update on the Pharmacogenomics of Proton Pump Inhibitors

A large segment of the CYP2C19 rapid metabolizer subgroup is nonresponder to the PPI treatment, only partial symptom relief in GERD, more frequent unsuccessful eradication therapy and lower healing ...
WRIC

Renexxion Ireland Ltd. Announces FDA Clearance of Investigational New Drug (IND) Application for Naronapride to Treat PPI-Non-Responsive Symptomatic GERD

ROSCREA, Ireland, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet ...